Shares of Autolus Therapeutics were up in trading after the company announced an exclusive licensing agreement with Moderna to develop new messenger RNA therapeutics for cancer.
If you are not happy with the results below please do another search
50 search results for:
Abbott Laboratories will pay $160 million to resolve claims that two of the company’s units submitted false claims to Medicare by providing kickbacks to diabetes patients, including “free” or “no cost” glucose monitors, the U.S. Department of Justice said.
Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).
AbbVie’s Rinvoq continues to demonstrate the medicine’s clinical potential to become the heir-apparent to the company’s blockbuster drug Humira, which will lose patent protection in 2023. In the company’s second-quarter 2021 report, AbbVie touted advances Rinvoq made throughout the three months, including positive Phase III data in ulcerative colitis.
With a new wave of Covid-19 infections fueled by the Delta variant striking countries worldwide, disease experts are scrambling to learn whether the latest version of coronavirus is making people – mainly the unvaccinated – sicker than before.
Combining AstraZeneca’s Covid-19 vaccine with a second dose from either Pfizer-BioNTech or Moderna’s jab provides “good protection”, Denmark’s State Serum Institute said on Aug. 2.
Calcium—a full-service, independent healthcare marketing agency—named Maha Elashri as Executive Vice President and Chief Client Officer.
AstraZeneca’s Saphnelo (anifrolumab-fnia) was approved in the United States for the treatment of adult patients with moderate to severe systemic lupus erythematosus who are receiving standard therapy.
The Olympics host city Tokyo, as well as Thailand and Malaysia, announced record Covid-19 infections on July 31, mostly driven by the highly transmissible Delta variant of the disease.
An Illinois jury on July 30 refused to hold Johnson & Johnson liable for a woman’s death from ovarian cancer, which her family blamed on decades of using the company’s talc-based powders.